Cytokine Synergy in Immunotherapy | p. 1 |
Monitoring Combination Therapy Trials: New Challenges for the Clinical Laboratory | p. 11 |
IL-2-Based Consolidative Immunotherapy After Autologous Bone Marrow Transplantation | p. 23 |
Tumor Immunogenicity Induced by the Local Occurrence of IL-2 | p. 31 |
Thymosin [alpha][subscript 1]: Chemistry, Mechanism of Action and Clinical Applications | p. 39 |
Combination Therapy with Thymosin [alpha][subscript 1] and Cytokines in the Treatment of Cancer and Infectious Diseases | p. 49 |
Effect of Thymosin [alpha][subscript 1] on Cocaine-induced Inhibition of T-Cell Dependent Murine Immune Response | p. 61 |
Regulation of Gene Expression by Interferons | p. 67 |
Interactions Between Tumor Necrosis Factor Alpha and Glucocorticoid Hormones in the Regulation of Tumor Cell Growth In Vitro | p. 71 |
Behavioural, Pyrogenic and Electrocortical Effects of Tumor Necrosis Factor-Alpha Given Intracerebrally in Rats | p. 81 |
Biological Significance and Therapeutic Potential of Tumor-Associated Leukocytes | p. 87 |
Septic Shock Pathophysiology: Focus on Therapeutic Approach | p. 95 |
Differentiating Agents and Cancer Therapy. Role of Cellular Lipid Peroxidation and its Product 4-Hydroxynonenal in the Control of Cell Proliferation and Differentiation | p. 105 |
Inhibition of HIV Replication and Enhancement of Immune Functions by the Acyclic Nucleoside Phosphonate 9-(2-Phosphonyl-Methoxyethyl) Adenine (PMEA) | p. 115 |
Modulation of Inflammatory Cytokines by a Receptor Antagonist, Autoantibodies, and Fever | p. 123 |
Cancer Immunochemotherapy: Preliminary Studies with Triazene Compounds | p. 135 |
Thymosin [alpha][subscript 1] and [alpha]-Interferon with Cisplatin and Etoposide in Advanced Non-Small Cell Lung Cancer: A Phase II Study | p. 149 |
Combination of Chronic Indomethacin and Intermittent IL-2 Therapy in the Treatment of Disseminated Cancer | p. 155 |
Combination Chemotherapy and Cytokines in the Treatment of Advanced Primary Lung Cancer: Results of a Controlled Clinical Trial | p. 167 |
Biological Response Modifiers and Differentiating Agents in Myelodisplastic Syndromes | p. 171 |
Myeloid Growth Factors in Cancer Treatment | p. 179 |
Efficacy of the Combined Treatment with Fluconazole and Thymosin [alpha][subscript 1] Against Candida albicans Infection in Morphine-Treated Mice | p. 189 |
Anti-Cytokine Therapy of Murine Candidiasis | p. 195 |
The Basic Research and Clinical Application of Thymopeptidin | p. 201 |
Treatment of Hepatitis C Virus-Associated Chronic Liver Disease with [beta]-Interferon and Inosine Pranobex: Combination Schedule vs. Monotherapies | p. 209 |
Sustained Response to Thymosin Therapy in Patients with Chronic Active Hepatitis B | p. 219 |
Combination Anti-HIV Therapy: Questions and Answers | p. 225 |
Mechanisms of Disease Progression and CD4 Depletion in HIV-1 Infection | p. 229 |
Combined Therapy with Zidovudine, Thymosin [alpha][subscript 1] and [alpha]-Interferon in the Treatment of HIV-Infected Patients | p. 235 |
The Problem of Interferon Species Appearing in Patients with Autoimmune Diseases | p. 243 |
Index | p. 251 |
Table of Contents provided by Blackwell. All Rights Reserved. |